HR-Positive Breast Cancer Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
HR-Positive Breast Cancer remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 8,224 matched trial records and 9,009 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600128155 | Intervention not normalized | Not Applicable; Not yet recruiting | The Affiliated Suzhou Hospital of Nanjing Medical University | China | Mean heart dose (After completion of radiotherapy treatment planning); CBCT setup error (Before each treatment fraction during CBCT verification) | 2028-12-31 |
| NCT07701070 | Intervention not normalized | Not Applicable; Not yet recruiting | AstraZeneca PLC | Geography not listed | Prevalence of ESR1 mutations in circulating tumour DNA (At baseline, approximately 3, 6, 9, 12, 15, and 18 months after initial testing); Emergence of ESR1 mutations during longitudinal ctDNA surveillance (At approximately 3, 6, 9, 12, 15, and 18 months after initial testing) | 2029-03-30 |
| NCT07701941 | Patritumab Deruxtecan + Fam-trastuzumab deruxtecan-NXKI | Phase 1/2; Not yet recruiting | Daiichi Sankyo Co., Ltd. | Geography not listed | Part 1: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) (Up to approximately 4.5 years); Part 2: Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v.1.1) as Assessed by the Investigator (Up to approximately 4.5 years) | 2031-01-01 |
| NCT07701018 | Intervention not normalized | Not Applicable; Not yet recruiting | University of Missouri-Kansas City | United States | Lymphatic Pain (Pre-intervention and 12 weeks post-intervention); Pain Severity and Interference (Pre-intervention and 12 weeks post-intervention) | 2027-12-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (Phase 1/2): the indexed record reports -; -; -.
- A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib Plus Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE) (Phase 3): the indexed record reports Persistent Wild Type n=76(Median) = 55.82 months (95% Confidence Interval, 39.06 - NA); -; -.
- A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations (Phase 2): the indexed record reports -; -; RCB-I = 1 Participants.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Patritumab Deruxtecan (Phase 3; HER3 x Top I), Fam-trastuzumab deruxtecan-NXKI (Approved; HER2 x Top I). Company & Deal Intelligence records identify sponsor context for The Affiliated Suzhou Hospital of Nanjing Medical University, AstraZeneca PLC (AZN), Daiichi Sankyo Co., Ltd. (4568), University of Missouri-Kansas City. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
HR-Positive Breast Cancer has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
